Emergent BioSolutions was not prepared to take on the mammoth task of churning out millions of COVID-19 vaccine doses to support U.S. efforts to end the pandemic, according to a report published today in The New York Times.
Emergent was ill-equipped despite a $163 million federal contract to prepare the facility for high-volume production, according to the Times investigation, which relied on previously undisclosed internal documents and interviews with current and former federal officials and former company workers.
The company — in a statement provided to MassDevice‘s sister site Pharmaceutical Processing World — said that any allegation that its safety, quality, and compliance systems are not working is false.
Get the full story on our sister site Pharmaceutical Processing World.